Literature DB >> 25942656

Therapy: SGLT2 inhibitor dapagliflozin promotes glucagon secretion in α islet cells.

Jennifer Sargent.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25942656     DOI： 10.1038/nrendo.2015.70

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

Authors:  Caroline Bonner; Julie Kerr-Conte; Valéry Gmyr; Gurvan Queniat; Ericka Moerman; Julien Thévenet; Cédric Beaucamps; Nathalie Delalleau; Iuliana Popescu; Willy J Malaisse; Abdullah Sener; Benoit Deprez; Amar Abderrahmani; Bart Staels; François Pattou
Journal:  Nat Med       Date:  2015-04-20       Impact factor: 53.440
  1 in total
  1 in total

Review 1.  SGLT2i: beyond the glucose-lowering effect.

Authors:  Lihua Ni; Cheng Yuan; Guopeng Chen; Changjiang Zhang; Xiaoyan Wu
Journal:  Cardiovasc Diabetol       Date:  2020-06-26       Impact factor: 9.951
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.